yingweiwo

Cysteine

Alias: Cysteinum; FEMA No. 3263; Cysteine
Cat No.:V19025 Purity: ≥98%
Cysteine is a novel and potent amino acid
Cysteine
Cysteine Chemical Structure CAS No.: 52-90-4
Product category: New1
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1g
Other Sizes

Other Forms of Cysteine:

  • L-Cysteine hydrochloride hydrate
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Cysteine is a novel and potent amino acid
Biological Activity I Assay Protocols (From Reference)
ADME/Pharmacokinetics
Metabolism / Metabolites
L-cysteine is a core compound in human sulfur metabolism. In proteins, the formation of disulfide bonds between cysteine sulfhydryl groups plays a crucial role in protein tertiary structure and enzyme activity; however, cysteine is always incorporated into polypeptide chains in its cysteine form. L-cysteine is degraded to pyruvate in two steps: desulfurization and transamination. Cysteine can be metabolized to taurine and carbon dioxide via the cysteine sulfinate pathway, the first step of which is the oxidation of cysteine to cysteine sulfinate. This step is catalyzed by cysteine dioxygenase. Cysteine sulfinate can be decarboxylated to taurine, or metabolized to pyruvate and sulfite via the putative intermediate β-sulfinylpyruvate, ultimately producing carbon dioxide and sulfate. Amino acid catabolism is essential for regulating the size of the free amino acid pool and participates in energy production and nutrient reuse. The carbon skeleton is typically converted into precursors or intermediates of the tricarboxylic acid cycle. For cysteine, the reduced sulfur derived from the thiol group must also be oxidized to prevent its accumulation to toxic concentrations. This article introduces a mitochondrial sulfur catabolism pathway that catalyzes the complete oxidation of L-cysteine to pyruvate and thiosulfate. After L-cysteine is transaminated to 3-mercaptopyruvate, its thiol group is transferred to glutathione via thiotransferase 1 and oxidized to sulfite by the sulfur dioxygenase ETHE1. Subsequently, thiotransferase 1 adds a second persulfate group, converting the sulfite to thiosulfate. This pathway is most important in early embryonic development and vegetative growth under light-limited conditions. Characterization of double mutants generated from Arabidopsis thaliana ETHE1 and thiotransferase 1 T-DNA insert lines revealed that intermediates in the ETHE1-dependent pathway (likely persulfates) interfere with amino acid catabolism and induce early senescence. Uremic toxins often accumulate in the blood due to overeating or poor renal filtration. Most uremic toxins are metabolic waste products, usually excreted in urine or feces.
Additional Infomation
L-cysteine is an optically active cysteine with an L-configuration. It is used as a flour treatment agent, a human metabolite, and an inhibitor of EC 4.3.1.3 (histidine ammonia-lyase). It is a serine family amino acid, a protein-synthesizing amino acid, cysteine, and an L-α-amino acid. It is the conjugate base of L-cysteine. It is the conjugate acid of L-cysteine (1-). It is the enantiomer of D-cysteine. It is the zwitterion tautomer of L-cysteine. Cysteine is a thiol-containing non-essential amino acid that can be oxidized to cystine. L-cysteine is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain). Cysteine has also been reported in Indigofera tinctoria, pomegranate, and other organisms with relevant data. Cysteine is an essential sulfur-containing amino acid for humans and is associated with cystine. Cysteine is crucial for protein synthesis, detoxification, and various metabolic functions. Cysteine is found in β-keratin, a major protein in nails, skin, and hair. Cysteine is crucial for collagen production and the elasticity and texture of the skin. It is also an essential amino acid for the synthesis of taurine, a component of the antioxidant glutathione, and plays a role in the metabolism of important biochemicals such as coenzyme A, heparin, and biotin. (NCI04)
Cysteine is a uremic toxin. Based on their chemical and physical properties, uremic toxins can be classified into three main categories: 1) small molecule, water-soluble, non-protein-bound compounds, such as urea; 2) small molecule, lipid-soluble, and/or protein-bound compounds, such as phenols; 3) larger so-called medium molecules, such as β2-microglobulin. Long-term exposure to uremic toxins can lead to various diseases, including kidney damage, chronic kidney disease, and cardiovascular disease.
Cysteine is a naturally occurring sulfur-containing amino acid found in most proteins, but in small amounts. Among the 20 naturally occurring amino acids, cysteine is unique in that it contains a sulfhydryl group. The thiol group can undergo redox reactions; cysteine, when oxidized, can form cystine, which is composed of two cysteine residues linked by a disulfide bond. This reaction is reversible: reducing the disulfide bond regenerates two cysteine molecules. The disulfide bond of cystine is crucial for the structure of many proteins. Cysteine commonly participates in electron transfer reactions and helps enzymes catalyze reactions. Cysteine is also a component of the antioxidant glutathione. N-acetyl-L-cysteine (NAC) is a form of cysteine in which the acetyl group is attached to the nitrogen atom of cysteine and is sold as a dietary supplement. The name cysteine comes from the Greek word kustis, meaning bladder—cysteine was originally isolated from kidney stones. Because cysteine contains a thiol group, it can undergo redox reactions. Oxidation of cysteine can form disulfide bonds with other thiols or be further oxidized to produce sulfinic acids or sulfonic acids. The thiol group of cysteine is also nucleophilic and can undergo addition and substitution reactions. Thiol groups exhibit significantly enhanced reactivity upon ionization. Cysteine residues in proteins have near-neutral pKa values, thus they typically exist intracellularly as reactive thiolates. Thiol groups have a high affinity for heavy metals, allowing cysteine-containing proteins to bind tightly to metals such as mercury, lead, and cadmium. Cysteine possesses antioxidant properties due to its redox capabilities. Cysteine is an important source of sulfur in human metabolism. Although classified as a non-essential amino acid, it may be essential for infants, the elderly, and individuals with certain metabolic disorders or malabsorption syndromes. In the future, cysteine may be recognized as an essential or conditionally essential amino acid. Cysteine plays a crucial role in energy metabolism. It exists in the form of cystine and is a structural component of many tissues and hormones. Cysteine has a wide range of clinical applications, from treating hair loss and psoriasis to preventing smoking-induced coughs. In some cases, oral cysteine therapy has proven highly effective in treating asthma and can help patients discontinue theophylline and other medications. In addition, cysteine can enhance the effectiveness of topical silver, tin, and zinc salts in preventing tooth decay. In the future, cysteine may play a role in treating cobalt poisoning, diabetes, mental illness, cancer, and epilepsy. Cysteine is a thiol-containing non-essential amino acid that oxidizes to form cystine. See also: Cysteine hydrochloride (salt form)... See more...
Drug Indications
For the prevention of liver and kidney damage caused by acetaminophen overdose
Mechanism of Action
Under normal physiological conditions, the human body can usually synthesize cysteine if methionine is sufficient. Cysteine is usually synthesized in the body when methionine is sufficient. Cysteine has antioxidant properties and participates in redox reactions. The antioxidant properties of cysteine are usually manifested in the tripeptide glutathione, which is present in the human body and other organisms. Due to the limited bioavailability of glutathione (GSH) in the body, it usually needs to be biosynthesized from its constituent amino acids—cysteine, glycine, and glutamate. Glutamic acid and glycine are abundant in the diets of most industrialized countries, but cysteine supply may be a limiting substrate. In human metabolism, cysteine participates as a precursor in the formation of iron-sulfur clusters and sulfides in nitrogenase. In a 1994 report by five top cigarette companies, cysteine was listed as one of 599 additives in cigarettes. However, like most cigarette additives, its use or purpose remains unclear. Adding cysteine to cigarettes may offer two benefits: firstly, as an expectorant, since smoking increases the production of mucus in the lungs; and secondly, by increasing the beneficial antioxidant glutathione (which is lower in smokers).
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C3H7NO2S
Molecular Weight
121.15
Exact Mass
121.019
CAS #
52-90-4
Related CAS #
62488-11-3;7048-04-6 (Hydrochloride)
PubChem CID
5862
Appearance
Colorless crystals
White crystals
Density
1.3±0.1 g/cm3
Boiling Point
293.9±35.0 °C at 760 mmHg
Melting Point
220 °C (dec.)(lit.)
Flash Point
131.5±25.9 °C
Vapour Pressure
0.0±1.3 mmHg at 25°C
Index of Refraction
1.550
LogP
0.23
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
4
Rotatable Bond Count
2
Heavy Atom Count
7
Complexity
75.3
Defined Atom Stereocenter Count
1
SMILES
S([H])C([H])([H])[C@@]([H])(C(=O)O[H])N([H])[H]
InChi Key
XUJNEKJLAYXESH-REOHCLBHSA-N
InChi Code
InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1
Chemical Name
(2R)-2-amino-3-sulfanylpropanoic acid
Synonyms
Cysteinum; FEMA No. 3263; Cysteine
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 8.2542 mL 41.2712 mL 82.5423 mL
5 mM 1.6508 mL 8.2542 mL 16.5085 mL
10 mM 0.8254 mL 4.1271 mL 8.2542 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05485558 Recruiting Drug: N-acetyl cysteine
Drug: Placebo
Drug Resistant Epilepsy Tanta University September 15, 2022 Phase 2
NCT02252341 Unknown Dietary Supplement: N-
Acetyl-Cysteine
Bipolar Disorder Universidade Estadual
de Maringá
September 2014 Phase 4
NCT03032601 Enrolling by invitation Dietary Supplement: N-
acetyl Cysteine
Multiple Sclerosis Thomas Jefferson University January 5, 2017 Not Applicable
NCT05122559 Recruiting Drug: N-acetyl cysteine
Drug: Placebo
Multiple Sclerosis Emmanuelle Waubant,
MD PhD
February 16, 2022 Phase 2
NCT06202911 Active, not recruiting Drug: oral n-acetyl cysteine Oral N-acetyl Cysteine Ain Shams University January 1, 2023 Phase 4
Biological Data
  • The effect of l-cysteine on food intake in rodents. (a) The effect of oral gavage administration of 4 mmol kg−1 (left panel) and of intraperitoneal administration of 2 mmol kg−1 (right panel) l-amino acids on 0–1-h food intake in the early light phase following an overnight fast, n=5–10. (b) The effect of oral administration of l- and d-cysteine and (c) the effect of intraperitoneal administration of l-cysteine on 0–1-h food intake during the early light phase after an overnight fast in male Wistar rats (n=6–8), and (d) the effect of oral and (e) intraperitoneal administration of l-cysteine on 0–1 h food intake during the early light phase after an overnight fast in male C57BL/6 mice (n=7–10). (f) The effect of oral administration 1, 2 and 4 mmol kg−1 l-cysteine and 127 mg kg−1 LiCl on conditioned 1 hour KoolAid consumption in male Wistar rats (n= 5–9). All data are expressed as mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001.[1].Int J Obes (Lond). 2015 Mar;39(3):447-55.
  • The effect of oral administration of l-cysteine on hypothalamic and brainstem cFos expression in rats. (a) Number of cFos-positive cells in the hypothalamic nuclei: AHA, ARC, DMN, LHA, PVN, VMN and brainstem nuclei: AP and NTS following oral gavage of water, 4 mmol kg−1 glycine or 4mmol kg−1 l-cysteine (n=3–6), data expressed as median and interquartile range, *P<0.05. (b) Representative sections of the AP (l-r: water, glycine, l-cysteine at −14.0 mm posterior from bregma) and (c) NTS (l-r: water, glycine, l-cysteine at −13.3.mm posterior from bregma), scale bar=50 μm.[1].Int J Obes (Lond). 2015 Mar;39(3):447-55.
  • The effect l-cysteine on gastric emptying and the role of the CCK-1R and vagal afferents. (a) The effect of IP administration of saline, 2 mmol kg−1 l-cysteine, glycine or 10 nmol kg−1 A71623, a CCK-1 receptor agonist, on gastric emptying of 2 ml of a semi-solid non-nutritive substance given by oral gavage in rats 30 min post injection relative to gastric emptying at time 0 (n=4–7). (b) The effect of IP administration of 0.5 mg kg−1 devazepide on the anorectic effect of 10 nmol kg−1 A71623 in the 0–1 h period post administration (n=8–9). (c) The effect of 0.5 mg kg−1 devazepide on the anorectic effect of 2 mmol kg−1 l-cysteine in the 0–1 h period post administration (n=8–9). (d) The effect of devazepide on the l-cysteine-induced delay in gastric emptying in mice (n=4–7). (e) The effect of oral gavage of water and 4 mmol kg−1 l-cysteine on 0–1 h food intake (n=9–10) in male Wistar rats having undergone sham or subdiaphragmatic vagal deafferentation (SDA). Data expressed as mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001.[1].Int J Obes (Lond). 2015 Mar;39(3):447-55.
Contact Us